ZeptoMetrix, an Antylia Scientific Company
TRONDHEIM, NORWAY / ACCESSWIRE / April 9, 2024 / Chiron AS, now part of ZeptoMetrix®, has developed the world's very first commercially available microplastic reference materials. This revolutionary new product range, called MicroPRefs®, was developed in close collaboration with the Norwegian Institute for Water Research (NIVA) and was made possible by grants from the EU project EUROqCHARM and Innovation Norway.
Microplastic particles are found in large quantities in water, soil, and in the air. Plastic pollution of various kinds breaks down in nature into tiny particles. These range in size from macro- to nano-sized particles. Microplastics are also carriers of various environmental toxins such as PFAS (per- and poly-fluoroalkyl substances) and brominated flame retardants, and cause significant environmental and health risks to communities around the world.
"In order to measure the quantity and type of microplastic substances present, there is a need for a yardstick or a 'reference material,' which is a material developed in the laboratory that can be used for comparison. ZeptoMetrix's Chiron AS business has now developed the very first commercially available microplastic reference materials for the six most abundant plastics in nature. New variants will follow successively throughout this year," stated Huiling Liu, Ph.D., Senior Director, R&D Analytical Reference Materials.
MicroPRefs® microplastic reference materials feature a novel tablet format containing a defined number of particles. The particles produced are of known plastic type and were designed to provide sizes and shapes that mimic microplastics found in nature. The tablets are dissolved in water and then analyzed using various methods and in parallel with real samples from nature.
The first single polymer tablets produced contain microplastic particles ranging in size between 50 and 300 micron. Multi-polymer tablets contain a mixture of three different plastic types. Further variants containing different size, quantity and combinations of plastics are planned to support researchers in their endeavors.
"The need to monitor microplastics in our surroundings is paramount to protecting the ongoing health of our communities. ZeptoMetrix is committed to fostering innovations that will help solve real-world issues as laboratories around the world can now deliver microplastics test results with greater confidence," stated Evangeline Gonzalez, President of ZeptoMetrix. "In addition, our scientists are partnering with industry organizations and leading laboratories to incorporate microplastics into our innovative proficiency testing programs."
About ZeptoMetrix
Chiron AS is part of ZeptoMetrix®, an Antylia Scientific company. ZeptoMetrix is the industry leader and manufacturer for innovative solutions solving challenges in the evolving Diagnostic Microbiology, Infectious Disease, and Oncology markets, as well as Analytical Reference Materials for the Applied Markets. We focus on our customers' success by providing premium product quality, reliability, and expert technical knowledge, enabling our customers to develop and advance many applications across diagnostics, pharmaceutical, environmental, food and beverage industries. From in-stock solutions to custom control and panel development, our scientific teams provide our customers with comprehensive, performance-oriented, and cost-effective products and services that positively impact the field of clinical diagnostics, analytical testing and contribute to a healthier world. ZeptoMetrix is a division of Antylia Scientific, an operating company of premier life science and diagnostic brands, including Cole-Parmer, Environmental Express and ZeptoMetrix.
Contact Information
Nancie Geddings
Global Business Development Leader
nancie.geddings@antylia.com
1-843-277-5230
Related Files
Chiron AS Develops the World's First Commercial Microplastic Reference Materials
SOURCE: ZeptoMetrix
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea
BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T
Picktan Capital Eyes a Public Listing on the LSE22.4.2025 09:10:00 CEST | Press release
Picktan Capital Explores Strategic Move Toward Public Listing on the London Stock Exchange in 2026. LONDON, UK / ACCESS Newswire / April 22, 2025 / Picktan Capital, the London-headquartered wealth management firm managing over $7 billion in client assets globally, has confirmed it is in active discussions with several major London-based investment banks to explore the possibility of a public listing on the London Stock Exchange (LSE) in 2026. The firm, known for its disciplined investment approach and bespoke wealth solutions, has formally notified its board of directors and shareholders of its intent to pursue a potential IPO. A strategic review process is currently underway to evaluate the most effective path to the public markets. At a recent shareholder meeting, the proposal to move forward with the listing received unanimous approval, highlighting widespread confidence in the company's direction, leadership, and future growth prospects. Founded with a mission to provide tailored,
ToolsGroup Recognized in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions for the Second Consecutive Year22.4.2025 09:00:00 CEST | Press release
As a trusted partner to retailers, distributors, and manufacturers, ToolsGroup drives results in an uncertain world BOSTON, MA / ACCESS Newswire / April 22, 2025 / ToolsGroup, a global leader in supply chain planning and optimization software, is proud to announce that it has been included in the 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions for the second consecutive year. For retailers, distributors, and manufacturers struggling to deliver results amidst uncertainty, ToolsGroup provides a breakthrough approach to supply chain planning that combines statistical modelling, advanced mathematical optimization, and AI. Customers have the power to shape demand and synchronize supply - replacing guesswork with precision. Built on decades of expertise and a unique probabilistic approach, ToolsGroup's Supply Chain Planning capabilities cover everything from S&OP and demand planning to inventory optimization, replenishment, and transport analytics. Powered by AI and real-time
IXOPAY Appoints Rachel Mae as Vice President of Sales to Execute Global Revenue Strategy Amid Accelerating Market Demand22.4.2025 06:00:00 CEST | Press release
Veteran sales leader joins IXOPAY to deepen customer engagement, expand international growth, and drive high-performance revenue strategy. LEHI, UT / ACCESS Newswire / April 22, 2025 / IXOPAY, a leading enterprise payment orchestration platform, today announced the appointment of Rachel Mae as Vice President of Sales. With over 20 years of experience building and leading high-performing sales organizations in software as a service (SaaS), financial technology (FinTech), and payments, Mae joins IXOPAY to scale the company's global revenue operations and expand its enterprise market footprint. Mae brings a proven track record of driving transformational sales strategies, enabling scalable growth, and developing customer-centric go-to-market teams. Her leadership will be instrumental as IXOPAY continues its global expansion and strengthens its position as the trusted partner for enterprises seeking resilience, flexibility, and optimization in their payment ecosystems. "Rachel brings the k
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom